BioSight
Companies
Agomab Therapeutics NV logo

AGMB

NASDAQANTWERPEN
Agomab Therapeutics NV

Agomab Therapeutics NV is a clinical-stage biopharmaceutical company focused on fibro-inflammatory diseases, with two lead programs: ontunisertib (AGMB-129), an oral small molecule TGF-beta receptor 1 inhibitor in Phase 2a development for fibrostenosing Crohn's disease, and AGMB-447, an inhaled small molecule TGF-beta receptor 1 inhibitor advancing toward Phase 2 studies in idiopathic pulmonary fibrosis. The company also has preclinical assets including AGMB-101, an HGF-mimetic monoclonal antibody designed to target fibrosis through MET receptor agonism, with regulatory clearance to initiate Phase 1 trials.

Price history not yet available for AGMB.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar